Olmesartan medoxomil (OLM) , is a diphenyl tetrazole analogue belonging to the class of angiotensin II receptor antagonists which is used clinically in treatment of hypertension. It is practically insoluble in water and has oral bioavailability of 26%. Solid lipid nanoparticles (SLN), have been developed for various routes of administration with several objectives including enhancement of bioavailability of poor water soluble drugs. OLM loaded SLN formulation was prepared by hot homogenization and ultra-sonication method. The SLN formulations were characterized and optimized..In-vitro drug release studies were performed using dialysis bag. The drug release kinetics of five optimized formulations were evaluated by fitting the data into various kinetics models. The characterization as well drug release studies data gave two optimized formulations (F3 and F7) which were used for pharmacokinetics studies. The formulations were found to enhance the bioavailability of OLM by 2.2 and 2.5 folds-increase respectively, compared to the aqueous solution of oral tablet.The work suggest that SLN formulation could be an effective oral drug delivery system to improve bioavailability of Olmesartan.
Ndidiamaka Hannah Okorie
Okorie Ndidiamaka H, Ph. D, is a Lecturer of Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences. Enugu State University of Science and Technology, Nigeria.
Chika, John Mbah
Anthony A. Attama
Number of Pages:
LAP LAMBERT Academic Publishing
Olmesartan Medoxomil, Solid Lipid Nanoparticles, invitro drug release, Bioavailability studies
MEDICAL / Pharmacology